Efficacy and safety of Atezolizumab plus Bevacizumab and Lenvatinib as first-line systemic therapies for hepatocellular carcinoma: A real-world study

• Sangdao Boonkaya,

  Roles Data curation, Formal analysis, Investigation, Project administration, Writing – original draft, Writing – review & editing

  Affiliations Division of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand, Department of Internal Medicine, Queen Savang Vadhana Memorial Hospital, Chonburi, Thailand

  https://orcid.org/0009-0005-2117-7467

  ⨯
• Chidkamon Pattarawongpaiboon,

  Roles Data curation

  Affiliation Division of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand

  https://orcid.org/0009-0008-0843-1311

  ⨯
• Panarat Thaimai,

  Roles Investigation

  Affiliation Division of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand

  ⨯
• Prooksa Ananchuensook,

  Roles Investigation

  Affiliations Division of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand, Center of Excellence in Hepatic Fibrosis and Cirrhosis, Chulalongkorn University, Bangkok, Thailand, Excellence Center in Liver Diseases, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand

  ⨯
• Supachaya Sriphoosanaphan,

  Roles Investigation

  Affiliations Division of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand, Center of Excellence in Hepatic Fibrosis and Cirrhosis, Chulalongkorn University, Bangkok, Thailand, Excellence Center in Liver Diseases, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand

  ⨯
• Suebpong Tanasanvimon,

  Roles Investigation, Supervision

  Affiliation Division of Oncology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

  ⨯
• Nattaya Teeyapun,

  Roles Investigation

  Affiliation Division of Oncology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

  ⨯
• Nussara Pakvisal,

  Roles Investigation

  Affiliation Division of Oncology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

  ⨯
• Nipaporn Siripon,

  Roles Investigation

  Affiliation Excellence Center in Liver Diseases, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand

  ⨯
• Sombat Treeprasertsuk,

  Roles Investigation, Supervision

  Affiliation Division of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand

  ⨯
• Piyawat Komolmit,

  Roles Conceptualization, Investigation, Resources, Supervision

  Affiliation Excellence Center in Liver Diseases, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand

  ⨯
• Kessarin Thanapirom

  Roles Conceptualization, Data curation, Resources, Supervision, Validation, Writing – review & editing

  * E-mail: kessarin.t@chula.ac.th

  Affiliations Division of Gastroenterology, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand, Center of Excellence in Hepatic Fibrosis and Cirrhosis, Chulalongkorn University, Bangkok, Thailand

  https://orcid.org/0000-0003-2333-1702

  ⨯